Table 2.
IBD treatments in the patient cohort.
| Treatment | Total (n) | Mild/Asymptomatic | Moderate/Severe | p |
|---|---|---|---|---|
| Anti-TNF | 52 | 50 | 2 | p = 0.002 |
| Vedolizumab | 23 | 22 | 1 | p = 0.084 |
| Ustekinumab | 12 | 10 | 2 | 1 |
| Other * | 7 | |||
| Total biologics | 94 | 87 | 7 | <0.001 |
| Biologics only | 76 | 71 | 5 | 0.001 |
| Biologics + steroids | 9 | 7 | 2 | 0.644 |
| Biologics + IM | 10 | 10 | 0 | 0.143 |
| IM monotherapy | 12 | 11 | 1 | 0.418 |
| Steroids only | 8 | 7 | 1 | 0.745 |
| IM monotherapy + steroids | 2 | 2 | 0 | 0.524 |
| 5-ASA | 29 | 25 | 4 | 0.642 |
| none | 18 | 7 | 11 | <0.001 |
* Other included tofacitinib and trial biologics treatments. IM; immunomodulators, including methotrexate.